Teva Strikes Two Settlements Over ‘Pay-For-Delay’ Agreements
A California Court has secured four major settlements worth $70m with pharmaceutical companies over allegations of entering into collusive pay-for-delay agreements, including two with Teva.
You may also be interested in...
The AAM has filed a lawsuit seeking an injunction to prevent the implementation of Californian legislation banning ‘pay-for-delay’ deals. The law is due to come into effect in January next year.
US off-patent industry association the AAM has blasted as unconstitutional a groundbreaking California law banning so-called ‘pay-for-delay’ deals under which brand companies pay rivals to keep generics off the market.
The US Federal Trade Commission (FTC) should “examine whether makers of biologic medicines are using strategies like ‘pay for delay’ to hinder or delay biosimilars from entering the market”, according to an open letter from US Senators Chuck Grassley and Amy Klobuchar to the US antitrust regulator.